By 2023, the global treatment-resistant depression treatment market size is predicted to reach a value of US$ 1.69 billion, with a projected compound annual growth rate (CAGR) of 9.0% between 2023 and 2033 due to the increasing prevalence of depression and anxiety disorders in adults and the aging population. By 2033, the market is estimated to expand to approximately US$ 4.0 billion. The rising awareness of treatment-resistant depression has led many market participants to develop advanced medications that can be delivered through intranasal and intravenous channels, as opposed to traditional oral administration.
Get a PDF Sample with Latest Market Insights@ https://www.futuremarketinsights.com/reports/sample/rep-gb-15965
While traditional antidepressants may take several weeks to have an impact and may result in partial or unsatisfactory outcomes when administered orally, intranasal administration has been shown to provide superior benefits within hours of delivery. For example, a study published in Pharmacopsychiatry in January 2022 showed that Novartis Pharmaceuticals’ MIJ821, an innovative pipeline antidepressant, produced a more significant reduction in depression episodes within 24 hours of monthly infusion among patients.
Moreover, the study demonstrated that intranasal esketamine, in combination with a novel oral antidepressant, was more effective than placebo plus oral delivery. Intranasal esketamine resulted in a rapid reduction in depression symptoms and delayed relapse time. Additionally, increased research and development of sophisticated pharmaceuticals using alternative modes of administration is expected to boost drug demand and drive overall market growth.
According to the World Health Organization (WHO), the prevalence of mental health disorders is increasing globally, with a 13% increase in the last decade. The U.S. Department of Health and Human Services (HHS) reports that in 2020, approximately 4.1 million adolescents aged 12 to 17 had a major depressive episode (MDE), and 2.9 million had an MDE with severe impairment.
Get a Discount@ https://www.futuremarketinsights.com/request-discount/rep-gb-15965
Key Takeaways from the Market Study
- Global treatment-resistant depression treatment market was valued at US$ 1.55 Billion by 2022-end
- From 2018 to 2022, the market demand expanded at a CAGR of 3.3%
- By drug type, the NMDA segment of the market constitutes the bulk of the market with a market share of 49%
- By Distribution Channel, the Hospital Pharmacies segment dominates the market with a share of 47%
- From 2023 to 2033, Treatment-Resistant Depression Treatment sales are expected to flourish at a CAGR of 9.0%.
- By 2033, the market value of Treatment-Resistant Depression Treatment is expected to reach US$ 4.0 Billion
“The rising geriatric population is one of the factors that is anticipated to boost the growth of treatment-resistance depression treatment market, as the treatment-resistance depression treatment is high in this age group population,” remarks an FMI analyst.
Competitive Landscape
Prominent players in the treatment-resistant depression treatment market are Janssen Global Services, LLC, AbbVie Inc., Sandoz International GmbH (Novartis AG), H. Lundbeck A/S, Par Pharmaceutical (Endo International plc), Otsuka Pharmaceutical Co., Ltd., and AstraZeneca, among others.
Customization Available Upon Request@ https://www.futuremarketinsights.com/customization-available/rep-gb-15965
Recent Developments:
- In August 2022, Merck Sharp & Dohme LLC initiated Phase IIa clinical trial to evaluate the safety and efficacy of MK-1942 among treatment-resistant depression patients.
- In July 2022, Novartis Pharmaceuticals announced that it would initiate a Phase 2 clinical trial of MIJ821 (ketamine) for treatment-resistant depressive disorders in September 2022.
- In May 2022, COMPASS Pathways presented positive data for Phase IIb study of COMP360 psilocybin therapy for treatment-resistant depression treatment at the American Psychiatric Association annual meeting in New Orleans.
- In February 2022, Denova Biopharma secured U.S. FDA approval to initiate a Phase 2b clinical trial to analyze the efficacy and safety of DB104 (liafensine) in patients with treatment-resistant mood disorder.
Key Segments Covered in the Treatment-Resistant Depression Treatment Industry Analysis
Treatment-Resistant Depression Treatment Market by Drug Type:
- NMDA
- Antidepressants
- Antipsychotics
- Others
Treatment-Resistant Depression Treatment Market by Distribution Channel:
- Hospital Pharmacies
- Drug Stores & Retail Pharmacies
- Online Pharmacies
Treatment-Resistant Depression Treatment Market by Region:
- North America
- Latin America
- Europe
- South Asia & Pacific
- East Asia
- Middle East & Africa
About Future Market Insights, Inc.
Future Market Insights, Inc. is an ESOMAR-certified business consulting & market research firm, a member of the Greater New York Chamber of Commerce and is headquartered in Delaware, USA. A recipient of Clutch Leaders Award 2022 on account of high client score (4.9/5), we have been collaborating with global enterprises in their business transformation journey and helping them deliver on their business ambitions. 80% of the largest Forbes 1000 enterprises are our clients. We serve global clients across all leading & niche market segments across all major industries.
Contact:
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Browse All Reports: https://www.futuremarketinsights.com/reports
LinkedIn| Twitter| Blogs